November 20, 2019
Two-Year ZILVERPASS Data Compares Cook Medical's Zilver PTX Versus Surgery
November 20, 2019—Cook Medical announced data supporting the use of the company’s Zilver PTX paclitaxel-coated stent for the treatment of peripheral artery disease (PAD) were presented by Marc Bosiers, MD, at the VEITHsymposium held November 19–23 in New York, New York.
According to the company, Dr. Bosiers presented 2-year data from the multicenter ZILVERPASS randomized controlled trial. The company-funded, physician-sponsored ZILVERPASS study is comparing the effects of treatment with Zilver PTX to traditional open prosthetic bypass surgery in 220 patients in four countries over 5 years.
In addition to the Zilver PTX procedure taking approximately half the time as bypass surgery, patients treated with the Zilver PTX stent had several benefits when compared with patients treated with traditional bypass surgery for PAD.
Patients treated with Zilver PTX had a hospital stay that was on average 5 days shorter. At 30 days after the procedure, patients treated with Zilver PTX for long and complex lesions were 60% less likely to have complications than patients who had bypass surgery. In addition, other clinical outcomes of Zilver PTX were comparable to those of bypass surgery, reported Cook Medical.